Evolent Health (NYSE:EVH) Rating Lowered to “Sector Weight” at KeyCorp

Evolent Health (NYSE:EVH) was downgraded by equities researchers at KeyCorp from an “overweight” rating to a “sector weight” rating in a research note issued to investors on Wednesday, Marketbeat reports.

Other equities analysts have also recently issued research reports about the stock. BMO Capital Markets initiated coverage on shares of Evolent Health in a research report on Thursday, November 13th. They issued an “outperform” rating and a $7.00 target price on the stock. Citizens Jmp reduced their price objective on Evolent Health from $11.00 to $10.00 and set a “market outperform” rating on the stock in a research note on Tuesday, January 6th. Canaccord Genuity Group lowered their target price on Evolent Health from $16.00 to $9.00 and set a “buy” rating for the company in a research note on Friday, November 14th. JPMorgan Chase & Co. dropped their target price on Evolent Health from $13.00 to $7.00 and set an “overweight” rating for the company in a report on Monday, November 17th. Finally, Citigroup reduced their price target on Evolent Health from $9.50 to $6.00 and set a “buy” rating on the stock in a research report on Friday, January 9th. Twelve equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Evolent Health has an average rating of “Moderate Buy” and a consensus target price of $6.50.

Evolent Health Stock Performance

Shares of NYSE EVH opened at $3.33 on Wednesday. The stock’s 50-day moving average is $3.50 and its 200 day moving average is $5.84. The stock has a market cap of $371.63 million, a price-to-earnings ratio of -0.65 and a beta of 0.27. Evolent Health has a 1-year low of $2.50 and a 1-year high of $12.06. The company has a current ratio of 1.33, a quick ratio of 1.33 and a debt-to-equity ratio of 1.25.

Evolent Health (NYSE:EVH) last issued its quarterly earnings results on Tuesday, February 24th. The technology company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. The business had revenue of $468.72 million for the quarter, compared to analysts’ expectations of $468.48 million. Evolent Health had a negative net margin of 28.49% and a positive return on equity of 1.30%. The business’s quarterly revenue was down 27.5% on a year-over-year basis. During the same period last year, the business earned ($0.02) earnings per share. On average, sell-side analysts anticipate that Evolent Health will post 0.08 EPS for the current fiscal year.

Institutional Trading of Evolent Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in Evolent Health by 0.4% during the 3rd quarter. Vanguard Group Inc. now owns 10,966,830 shares of the technology company’s stock valued at $92,779,000 after purchasing an additional 45,299 shares during the period. Durable Capital Partners LP purchased a new position in shares of Evolent Health during the second quarter valued at about $72,326,000. Eventide Asset Management LLC increased its position in shares of Evolent Health by 54.0% during the third quarter. Eventide Asset Management LLC now owns 6,292,511 shares of the technology company’s stock valued at $53,246,000 after buying an additional 2,205,659 shares during the period. Engaged Capital LLC raised its stake in Evolent Health by 13.0% in the second quarter. Engaged Capital LLC now owns 5,854,468 shares of the technology company’s stock worth $65,921,000 after buying an additional 675,000 shares in the last quarter. Finally, Rubicon Founders LLC purchased a new stake in Evolent Health in the third quarter worth about $49,204,000.

More Evolent Health News

Here are the key news stories impacting Evolent Health this week:

• Positive Sentiment: Q4 earnings beat — Evolent posted $0.08 EPS vs. consensus $0.06, turning profitable year-over-year and giving investors a near-term catalyst. Evolent Health (EVH) Q4 Earnings Top Estimates
• Positive Sentiment: Management to participate in investor conferences with live webcasts — increases visibility and gives investors direct access to management’s strategy and outlook. Evolent to Participate in Upcoming Investor Conferences
• Positive Sentiment: Some analysts maintain buy ratings and still show upside — BTIG (new $8 PT) and UBS (new $5 PT) kept buy calls, signaling continued institutional conviction despite lower targets. Evolent Health (NYSE:EVH) Given New $8.00 Price Target at BTIG Research
• Neutral Sentiment: Market commentary and analysis highlight turnaround potential and technical momentum — pieces noting EVH as “cheap, levered, but ready to rebound” and coverage of the intraday move provide narrative context rather than new fundamentals. Evolent Health: Cheap, Levered, But Ready To Rebound
• Neutral Sentiment: Investor note/roundups covering the share move summarize news flow for traders but don’t add new company data. Evolent Health (EVH) Shares Skyrocket, What You Need To Know
• Negative Sentiment: Multiple price-target cuts and a downgrade — several firms lowered PTs (Needham, Citi, RBC, UBS) and KeyCorp downgraded EVH to sector weight, which increases near-term downside risk and reflects investor concerns about top-line declines and leverage. Benzinga coverage of analyst actions
• Negative Sentiment: Revenue decline and margin pressure remain issues — revenue was roughly flat to consensus but down year-over-year, and the company still reports negative net margins, which could limit investor enthusiasm absent clear margin improvement. Evolent Health, Inc. Q4 2025 Earnings Call Transcript

Evolent Health Company Profile

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.